NASDAQ:SGRY - Surgery Partners Stock Price, Price Target & More

Surgery Partners trades on the NASDAQ under the ticker symbol "SGRY."

Surgery Partners declared that its board has authorized a share buyback program on Saturday, December 16th 2017, which authorizes the company to repurchase $50,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

Surgery Partners (NASDAQ:SGRY) released its quarterly earnings results on Thursday, March, 1st. The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of $0.08 by $0.11. The company had revenue of $460.30 million for the quarter, compared to the consensus estimate of $438.30 million. Surgery Partners had a negative return on equity of 0.53% and a negative net margin of 4.54%. Surgery Partners's revenue for the quarter was up 50.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.35 earnings per share. View Surgery Partners' Earnings History.

Surgery Partners is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Surgery Partners.

8 brokerages have issued 12 month price objectives for Surgery Partners' stock. Their predictions range from $15.00 to $19.00. On average, they anticipate Surgery Partners' share price to reach $17.6667 in the next twelve months. View Analyst Ratings for Surgery Partners.

Some companies that are related to Surgery Partners include Repligen (RGEN), Xencor (XNCR), Innoviva (INVA), Tivity Health (TVTY), Atara Biotherapeutics (ATRA), Akcea Therapeutics (AKCA), Radius Health (RDUS), Momenta Pharmaceuticals (MNTA), Sirtex Medical (SRX), Mazor Robotics (MZOR), HMS (HMSY), Irhythm Technologies (IRTC), Prothena (PRTA), Ensign Group (ENSG), Impax Laboratories (IPXL), Audentes Therapeutics (BOLD), Pacira Pharmaceuticals (PCRX) and Varex Imaging (VREX).

News articles about SGRY stock have trended very positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Surgery Partners earned a daily sentiment score of 0.53 on Accern's scale. They also assigned media stories about the company an impact score of 45.22 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Surgery Partners' stock is owned by a variety of of institutional and retail investors. Top institutional investors include DOYLE MICHAEL THOMAS (6.10%) and DOYLE MICHAEL THOMAS (6.10%). Company insiders that own Surgery Partners stock include HIG Surgery Centers, Llc and Jennifer Baldock. View Institutional Ownership Trends for Surgery Partners.

Shares of SGRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SGRY stock can currently be purchased for approximately $17.48.

Surgery Partners has a market capitalization of $833.69 million and generates $1.34 billion in revenue each year. The company earns $-52,980,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Surgery Partners employs 10,600 workers across the globe.

Surgery Partners' mailing address is 310 Seven Springs Way Suite 500, Brentwood TN, 37027. The company can be reached via phone at 615-234-5900 or via email at [email protected]